{"organizations": [], "uuid": "9e8ed07084d02111dfb6a2e2f320b95c212744db", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-compugen-ltd-bayer-plans-to-advanc/brief-compugen-ltd-bayer-plans-to-advance-cancer-immunotherapy-program-into-first-in-human-trials-in-2018-idUSFWN1RU0SG", "country": "US", "domain_rank": 408, "title": "BRIEF-Compugen Ltd - Bayer Plans To Advance Cancer Immunotherapy Program Into First-In-Human Trials In 2018", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-17T14:07:00.000+03:00", "replies_count": 0, "uuid": "9e8ed07084d02111dfb6a2e2f320b95c212744db"}, "author": "", "url": "https://www.reuters.com/article/brief-compugen-ltd-bayer-plans-to-advanc/brief-compugen-ltd-bayer-plans-to-advance-cancer-immunotherapy-program-into-first-in-human-trials-in-2018-idUSFWN1RU0SG", "ord_in_thread": 0, "title": "BRIEF-Compugen Ltd - Bayer Plans To Advance Cancer Immunotherapy Program Into First-In-Human Trials In 2018", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "bayer", "sentiment": "negative"}, {"name": "brief-compugen ltd", "sentiment": "negative"}, {"name": "compugen ltd", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 17, 2018 / 11:08 AM / Updated 21 minutes ago BRIEF-Compugen Ltd - Bayer Plans To Advance Cancer Immunotherapy Program Into First-In-Human Trials In 2018 Reuters Staff 1 Min Read \nApril 17 (Reuters) - Compugen Ltd: \n* COMPUGEN LTD - BAYER PLANS TO ADVANCE CANCER IMMUNOTHERAPY PROGRAM INTO FIRST-IN-HUMAN TRIALS IN 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)", "external_links": [], "published": "2018-04-17T14:07:00.000+03:00", "crawled": "2018-04-17T14:19:53.003+03:00", "highlightTitle": ""}